WuXi Biologics (Cayman) Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WXIBF research report →
Companywww.wuxibiologics.com
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities.
- CEO
- Zhisheng Chen
- IPO
- 2018
- Employees
- 12,575
- HQ
- Wuxi, CN
Price Chart
Valuation
- Market Cap
- $17.28B
- P/E
- 24.54
- P/S
- 5.42
- P/B
- 2.55
- EV/EBITDA
- 14.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 45.98%
- Op Margin
- 30.47%
- Net Margin
- 22.53%
- ROE
- 10.64%
- ROIC
- 9.26%
Growth & Income
- Revenue
- $21.23B · 13.67%
- Net Income
- $4.78B · 42.48%
- EPS
- $1.19 · 45.12%
- Op Income
- $6.47B
- FCF YoY
- 117.37%
Performance & Tape
- 52W High
- $5.61
- 52W Low
- $2.85
- 50D MA
- $4.51
- 200D MA
- $4.55
- Beta
- 0.58
- Avg Volume
- 512
Get TickerSpark's AI analysis on WXIBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our WXIBF Coverage
We haven't published any research on WXIBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate WXIBF Report →